TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03166007

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Optimised bowel care
Description: During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimised bowel care
Description: During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
Study: NCT02518074

Intervention type: OTHER
Group type: OTHER
Intervention: Hearing and Vestibular Interactions
Description: in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
Study: NCT02933723

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draw
Description: Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Draw
Description: Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
Study: NCT04343469

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric Surgery (RYGB or LSG)
Description: Morbidly obese subjects will receive either RYGB or LSG, and the effect of bariatric surgery-induced weight loss on brain inflammation will be assessed
Study: NCT06051370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided glenohumeral space triamcinolone, lidocaine and saline injection
Description: Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the glenohumeral space through the posterior approach
Study: NCT03039348

Intervention type: OTHER
Intervention: semi-structured interview using a questionnaire
Description: semi-structured interview using a questionnaire

Intervention type: OTHER
Intervention: semi-structured interview using a questionnaire
Description: semi-structured interview using a questionnaire
Study: NCT04339426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone/Azithromycin
Description: Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
Study: NCT02932020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AlloGen-LI
Description: interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI

Intervention type: DRUG
Group type: OTHER
Intervention: depomedrol
Description: interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% marcaine
Description: epidural injection of 2mL 0.5% marcaine
Study: NCT06051370

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided subacromial space triamcinolone, lidocaine and saline injection
Description: Using a 21-gauge spinal needle, the predefined steroid solution was injected under ultrasound guidance using 5- to 13-MHz linear probe into the subacromial space through the anterolateral approach
Study: NCT02932020

Intervention type: DRUG
Group type: OTHER
Intervention: 0.5% marcaine
Description: epidural injection of 2mL 0.5% marcaine
Study: NCT06063096

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-allulose
Description: Fruit-flavoured drink with d-allulose at 2 dosages

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: D-allulose
Description: Fruit-flavoured drink with d-allulose at 2 dosages
Study: NCT03680690

Intervention type: PROCEDURE
Intervention: hysteroscopy
Description: office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.

Intervention type: PROCEDURE
Intervention: hysteroscopy
Description: office hysteroscopy will be done for all candidates and operative correction of detected lesions will be carried on.
Study: NCT00158574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulphadoxine-pyrimethamine
Study: NCT06063096

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fruit-flavoured drink with high fructose corn syrup
Study: NCT00140413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin AQ
Description: Daily injection. Dosage dependent on weight.
Study: NCT04352608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Description: Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Description: Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,14 in phaseⅡ.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the emergency vaccination schedule
Description: Two doses of placebo at the schedule of day 0,14 and one dose of booster immunization with placebo 6 months after the schedule of day 0,14 in phaseⅡ.
Study: NCT00158574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mefloquine
Study: NCT04352608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Description: Two doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with medium dosage (600SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Description: Two doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28 and one dose of booster immunization with high dosage (1200SU/0.5ml) experimental vaccine 6 months after the schedule of day 0,28 in phaseⅡ

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the routine vaccination schedule
Description: Two doses of placebo at the schedule of day 0,28 and one dose of booster immunization with placebo 6 months after the schedule of day 0,28 in phaseⅡ.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Description: Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,14,42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Description: Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,14,42

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the emergency vaccination schedule
Description: Three doses of placebo at the schedule of day 0,14,42

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Description: Three doses of medium dosage (600SU/0.5ml) experimental vaccine at the schedule of day 0,28,56

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Description: Three doses of high dosage (1200 SU/0.5ml) experimental vaccine at the schedule of day 0,28,56
Study: NCT03078036

Intervention type: GENETIC
Intervention: Germline BRCA Test (blood)
Description: If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)

Intervention type: GENETIC
Intervention: FoundationOne Dx Genomic Profile (archival Tumour Specimen)
Description: Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:~* Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.~* Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile.
Study: NCT04352608

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the routine vaccination schedule
Description: Three doses of placebo at the schedule of day 0,28,56
Study: NCT01389934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levo-bupicaine
Description: Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women of this group be infused saline 2 ml / h for 48h.
Study: NCT02610413

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03787329

Intervention type: OTHER
Intervention: Core decompression surgery with bone marrow concentration
Description: Core decompression surgery with bone marrow concentration

Intervention type: OTHER
Intervention: Core decompression surgery
Description: Core decompression surgery only
Study: NCT02891226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03078036

Intervention type: OTHER
Intervention: Follow-up
Description: Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.~- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study.
Study: NCT04479917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H
Description: Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Study: NCT03337555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath
Description: McGrath videolaryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pentax
Description: Pentax videolaryngoscope
Study: NCT03363477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clexane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clexane
Study: NCT03036839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
Study: NCT03337555

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh
Description: Macintosh direct laryngoscope
Study: NCT02381496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 1 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 3 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 10 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 10 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 30mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 100 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 100 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 300 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 800 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-453859 800 mg
Description: Capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule
Study: NCT03036839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg fixed- dose combination (FDC) tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
Study: NCT03938129

Intervention type: OTHER
Intervention: Blood sample
Description: 1st trimester blood sample for bio-bank

Intervention type: OTHER
Intervention: Urine sample
Description: 1st trimester urine sample for bio-bank

Intervention type: OTHER
Intervention: Pregnancy, maternal health, and fetal health data
Description: Pregnancy, maternal health, and fetal health data
Study: NCT02947724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL®
Description: Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SURGICEL®
Description: Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
Study: NCT02381496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching ACT-453859 placebo capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setipiprant 500 mg
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setipiprant 1000 mg
Description: Capsule
Study: NCT01999946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Naltrexone
Description: Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
Study: NCT02916693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: FDA-approved, beta 3 agonist for over active bladder
Study: NCT01563926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
Study: NCT04133649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV-hTERT
Description: subjects will receive a single LGT (AAV-hTERT) treatment via IV administration
Study: NCT02486913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Health Check
Description: National Health Service Health Check enhanced by risk report
Study: NCT01921933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow
Description: The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
Study: NCT01743014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
Study: NCT02388022

Intervention type: DEVICE
Intervention: Degenerative Disc Disease
Description: lumbar interbody with posterior screw and rod instrumentation
Study: NCT02019394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AE58054
Description: Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.~Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10.
Study: NCT05679973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polybutester suture
Description: After third molar surgery this suture used for primary closure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polypropylene suture
Description: After third molar surgery this suture used for primary closure.
Study: NCT02213952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma
Description: For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment
Description: Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
Study: NCT04447937

Intervention type: OTHER
Intervention: No Interventions
Description: There are no interventions associated with the study.
Study: NCT02199678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine 25 mg
Description: ketamine
Study: NCT02159469

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate auto-injector
Description: Dose Adjustment to 50 mg or 75 mg or 100 mg based upon Testosterone levels
Study: NCT00158574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pryrimethamine
Description: IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
Study: NCT02199678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine 35 mg
Description: ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine 50 mg
Description: ketamine
Study: NCT02370914

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: Recording of subjects with Nautilus NeuroWave diagnostic device

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: Recording of subjects with Nautilus NeuroWave diagnostic device

Intervention type: BEHAVIORAL
Intervention: SCAT
Description: A Neurocognitive evaluation of the patients to assess for concussion.

Intervention type: BEHAVIORAL
Intervention: SCAT
Description: A Neurocognitive evaluation of the patients to assess for concussion.
Study: NCT00356824

Intervention type: DRUG
Intervention: Amodiaquine
Description: 200 mg oral tablet taken daily for 3 days under direct supervision at study clinic

Intervention type: DRUG
Intervention: Artesunate
Description: 50 mg oral tablet taken daily for 3 days under direct supervision at study clinic